Masoud Tavazoie, M.D., Ph.D.
Chief Executive Officer & Co-founder
Masoud is co-founder, Board Director, and the Chief Executive Officer of Rgenix.
David Darst, M.B.A.
CHIEF OPERATING OFFICER
David co-leads Rgenix’s financing, corporate development, and drug development efforts.
Robert Wasserman, M.D.
Chief Medical Officer
Bob oversees clinical development of Rgenix’s first-in-class programs.
Isabel Kurth, Ph.D.
VP of Research
Isabel leads Rgenix’s research and target discovery efforts.
Stephen Wald
VP of Chemistry & Pharmaceutical Sciences
Steve is responsible for chemical, analytical and formulation development, and manufacturing scale-up, of Rgenix’s drug candidates.
Foster Gonsalves, Ph.D., M.P.H.
VP of Drug Development & Strategy
Foster currently heads translational development of Rgenix’s pipeline and leads the implementation of the biomarker and diagnostic strategy. He is also a key member of the corporate strategy team.
Corey Sohmer, M.B.A.
VP of Finance & Accounting
Corey brings to Rgenix more than 25 years of progressive leadership experience in finance and accounting.
Michael Szarek, Ph.D.
VP of Clinical & Regulatory Affairs
Michael leads clinical and regulatory affairs at Rgenix.
